首页 | 本学科首页   官方微博 | 高级检索  
     

血管生成拟态和马赛克血管与肾癌的靶向治疗
引用本文:Deng JH,Li HZ. 血管生成拟态和马赛克血管与肾癌的靶向治疗[J]. 中国医学科学院学报, 2011, 33(4): 462-467. DOI: 10.3881/j.issn.1000-503X.2011.04.023
作者姓名:Deng JH  Li HZ
作者单位:中国医学科学院北京协和医学院 北京协和医院泌尿外科,北京,100730
摘    要:肾癌是泌尿系统最常见的恶性肿瘤之一,年发病率为17.9/10万,有逐年增加趋势.转移性和高危肾细胞癌预后差,且对化疗和/或放疗均不敏感.虽然细胞因子(干扰素和白介素-2)治疗被广泛应用,但因其反应率低和生存期短,故而疗效欠佳.针对抗血管生成途径,运用靶向药物行术前辅助或术后辅助治疗肾细胞癌显著提高了患者的无复发存活率.本文主要综述从基础到临床,尤其是有关血管生成拟态和马赛克血管在肾癌治疗中的一些重要进展.虽然抗血管生成的靶向治疗已确立了治疗转移性肾癌的新标准,但是仍需要新的药物或联用来提高疗效,减少药物相关的毒性.

关 键 词:肾细胞癌  血管生成拟态  马赛克血管  靶向治疗

Vasculogenic mimicry and mosaic vessels and targeted therapy in renal cell carcinoma
Deng Jian-hua,Li Han-zhong. Vasculogenic mimicry and mosaic vessels and targeted therapy in renal cell carcinoma[J]. Acta Academiae Medicinae Sinicae, 2011, 33(4): 462-467. DOI: 10.3881/j.issn.1000-503X.2011.04.023
Authors:Deng Jian-hua  Li Han-zhong
Affiliation:DENG Jian-hua,LI Han-zhong Department of Urology,PUMC Hospital,CAMS and PUMC,Beijing 100730,China
Abstract:Renal cell carcinoma is one of the most common malignant tumors of urinary system.The annual incidence rate is approximately 17.9/100 000 populations,and there is a continually rising trend in number of new diagnosis.Metastatic and high-risk renal cell cancer is associated with a poor prognosis and is resistant to traditional chemotherapy and/or radiotherapy.Although cytokine-based therapied(interferon and interleukin-2) have been widely used,their effectiveness remained unsatisfactory due to their low resp...
Keywords:renal cell carcinoma  vasculogenic mimicry  mosaic vessels  targeted therapy  
本文献已被 CNKI 万方数据 PubMed 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号